Skip to main content

Table 3 Demographic and clinical characteristics of the sample excluding the individuals carrying a TREM2 rare variant

From: Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology

  CDR = 0 (n = 291) CDR = 0.5 (n = 587) CDR = 1 (n = 104)
  A-/TN- (n = 122) A+/TN- (n = 52) A+/TN+ (n = 45) A-/TN+ (n = 72) A-/TN- (n = 118) A+/TN- (n = 93) A+/TN+ (n = 282) A-/TN+ (n = 94) A-/TN- (n = 2) A+/TN- (n = 15) A+/TN+ (n = 80) A-/TN+ (n = 7)
Age, y 72.5 (5.50) 73.5 (5.95) 76.3 (5.46) 74.6 (6.56) 69.9 (7.56) 72.6 (7.74) 73.3 (7.08) 73.2 (8.16) 89.2 (1.63) 76.3 (6.05) 74.1 (9.28) 79.8 (8.02)
Female, n (%) 58 (47.5) 24 (46.2) 24 (53.3) 40 (55.6) 55 (46.6) 21 (22.6) 119 (42.2) 42 (44.7) 0 (0) 5 (33.3) 40 (50.0) 2 (28.6)
APOE ε4 carriers, n (%) 17 (13.9) 20 (38.5) 27 (60.0) 15 (20.8) 24 (20.3) 47 (50.5) 216 (76.6) 32 (34.0) 0 (0) 8 (53.3) 59 (73.8) 1 (14.3)
Education, y 16.4 (2.79) 16.0 (2.65) 16.5 (2.55) 16.4 (2.57) 16.0 (2.68) 16.1 (2.97) 15.9 (2.90) 15.9 (2.66) 17.0 (0) 16.2 (2.51) 15.1 (2.80) 15.0 (2.08)
CSF biomarkers, pg/ml*
 T-tau 185 (32.2) 167 (40.5) 332 (79.3) 322 (71.9) 183.4 (38.2) 173 (40.0) 381 (136) 338 (111) 234 (6.08) 188 (38.8) 393 (136) 489 (221)
 P-tau181P 16.2 (2.88) 15.4 (4.07) 33.3 (9.09) 28.9 (7.43) 15.8 (3.32) 15.9 (4.14) 38.9 (14.7) 31.6 (13.7) 19.3 (1.20) 17.4 (3.53) 39.2 (15.0) 43.2 (22.9)
 Aβ1-42 1456 (223) 723 (196) 717 (168) 1538 (235) 1428 (247) 632 (196) 634 (168) 1427 (290) 1330 (14.9) 538 (185) 570 (159) 1484 (290)
 sTREM2 3741 (1690) 2835 (1524) 4839 (2240) 5378 (2147) 3436 (1754) 2791 (1292) 4441 (2211) 5478 (2370) 5660 (2008) 3051 (1128) 3967 (2000) 7619 (3539)
  1. Data are expressed as mean and standard deviation (SD) or number (n) and percentage (%), as appropriate.
  2. *The CSF core biomarkers measurements were performed using the electrochemiluminiscence immunoassays Elecsys Total-tau CSF, phosphor-tau(181P) CSF and β-amyloid(1-42) CSF, which have an upper technical limit of 1300 pg/ml (T-tau), 120pg/ml (P-tau181P) or 1700 pg/ml (Aβ1-42). The values above these limits were truncated to the respective upper technical limit.
  3. Abbreviations: A Aβ pathology biomarker status, 1-42 amyloid-β 42, APOE apolipoprotein E, CDR clinical dementia rating, CSF cerebrospinal fluid, N neurodegeneration biomarker status, P-tau181P tau phosphorylated at threonine 181, T tau pathology biomarker status, T-tau total tau, y year